Tulissin

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

тулатромицин

Available from:

Virbac S.A.

ATC code:

QJ01FA94

INN (International Name):

tulathromycin

Therapeutic group:

Cattle; Pigs; Sheep

Therapeutic area:

Антибактериални средства за системна употреба

Therapeutic indications:

Cattle: Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis susceptible to tulathromycin. Наличието на болестта в стадото трябва да бъде установено преди метафилактичното лечение. Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis susceptible to tulathromycin. Pigs: Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica susceptible to tulathromycin. Наличието на болестта в стадото трябва да бъде установено преди метафилактичното лечение. The product should only be used if pigs are expected to develop the disease within 2–3 days. Овца: лечение на ранните стадии на инфекцията pododermatitis (копытная гниене), свързани с вирулентным пилей dichelobacter nodosus, които изискват системно лечение.

Product summary:

Revision: 3

Authorization status:

упълномощен

Authorization date:

2020-04-24

Patient Information leaflet

                                36
B. ЛИСТОВКА
37
ЛИСТОВКА:
TULISSIN 100 MG/ML ИНЖЕКЦИОНЕН РАЗТВОР ЗА
ГОВЕДА, СВИНЕ И ОВЦЕ
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба:
VIRBAC
1
ère
avenue 2065m LID
06516 Carros
France
Производител, отговорен за
освобождаване на партидата:
VIRBAC
1
ère
avenue 2065m LID
06516 Carros
France
FAREVA
Zone Industrielle,
29 route des Industries
37530 Pocé-sur-Cisse
France
Отпечатаната листовка на
ветеринарномедицинския продукт
трябва да съдържа името и адреса
на производителя, отговорен за
освобождаване на съответната партида.
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Tulissin 100 mg/ml инжекционен разтвор за
говеда, свине и овце
tulathromycin
3.
СЪДЪРЖАНИЕ НА АКТИВНАТА СУБСТАНЦИЯ И
ЕКСЦИПИЕНТИТЕ
Всеки 1 ml съдържа:
АКТИВНА СУБСТАНЦИЯ:
Tulathromycin
100 mg
ЕКСЦИПИЕНТИ:
Monothioglycerol
5 mg
Бистър, безцветен до слабо оцветен
разтвор.
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Говеда
Лечение и метафилаксия на
респираторни заболявания при говеда
(BRD), причинени от
_Mannheimia haemolytica_
,
_Pasteurella multocida, Histophilus somni _
и
_Mycoplasma bovis_
,
чувствителни към tulathromycin. Преди
употребата на продукта трябва да бъде
установено
наличие на заболяването в групата.
38
Лечение на инфекциозен
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Tulissin 100 mg/ml инжекционен разтвор за
говеда, свине и овце
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всеки 1 ml съдържа:
АКТИВНА СУБСТАНЦИЯ:
Tulathromycin
100 mg
ЕКСЦИПИЕНТИ:
Monothioglycerol
5 mg
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Инжекционен разтвор.
Бистър, безцветен до слабо оцветен
разтвор.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Говеда, свине и овце.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
Говеда
Лечение и метафилаксия на
респираторни заболявания при говеда
(BRD), причинени от
_Mannheimia haemolytica_
,
_Pasteurella multocida, Histophilus somni _
и
_Mycoplasma bovis_
,
чувствителни към tulathromycin. Преди
употребата на продукта трябва да бъде
установено
наличие на заболяването в групата.
Лечение на инфекциозен
кератоконюнктивит по говедата (IBK),
причинен от
_Moraxella bovis_
,
чувствителна към tulathromycin.
Свине
Лечение и метафилаксия на
респираторни заболявания при свине
(SRD), причинени от
_Actinobacillus pleuropneumoniae_
,
_Pasteurella multocida, Mycoplasma hyopneumoniae_
,
_Haemophilus _
_parasuis _
и
_Bordetella bronchiseptica, _
чувствителни към tulathromycin. Преди
употребата н
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 07-12-2021
Public Assessment Report Public Assessment Report Spanish 26-06-2020
Patient Information leaflet Patient Information leaflet Czech 07-12-2021
Public Assessment Report Public Assessment Report Czech 26-06-2020
Patient Information leaflet Patient Information leaflet Danish 07-12-2021
Public Assessment Report Public Assessment Report Danish 26-06-2020
Patient Information leaflet Patient Information leaflet German 07-12-2021
Public Assessment Report Public Assessment Report German 26-06-2020
Patient Information leaflet Patient Information leaflet Estonian 07-12-2021
Public Assessment Report Public Assessment Report Estonian 26-06-2020
Patient Information leaflet Patient Information leaflet Greek 07-12-2021
Public Assessment Report Public Assessment Report Greek 26-06-2020
Patient Information leaflet Patient Information leaflet English 07-12-2021
Public Assessment Report Public Assessment Report English 26-06-2020
Patient Information leaflet Patient Information leaflet French 07-12-2021
Public Assessment Report Public Assessment Report French 26-06-2020
Patient Information leaflet Patient Information leaflet Italian 07-12-2021
Public Assessment Report Public Assessment Report Italian 26-06-2020
Patient Information leaflet Patient Information leaflet Latvian 07-12-2021
Public Assessment Report Public Assessment Report Latvian 26-06-2020
Patient Information leaflet Patient Information leaflet Lithuanian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-12-2021
Public Assessment Report Public Assessment Report Lithuanian 26-06-2020
Patient Information leaflet Patient Information leaflet Hungarian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 07-12-2021
Public Assessment Report Public Assessment Report Hungarian 26-06-2020
Patient Information leaflet Patient Information leaflet Maltese 07-12-2021
Public Assessment Report Public Assessment Report Maltese 26-06-2020
Patient Information leaflet Patient Information leaflet Dutch 07-12-2021
Public Assessment Report Public Assessment Report Dutch 26-06-2020
Patient Information leaflet Patient Information leaflet Polish 07-12-2021
Public Assessment Report Public Assessment Report Polish 26-06-2020
Patient Information leaflet Patient Information leaflet Portuguese 07-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 07-12-2021
Public Assessment Report Public Assessment Report Portuguese 26-06-2020
Patient Information leaflet Patient Information leaflet Romanian 07-12-2021
Public Assessment Report Public Assessment Report Romanian 26-06-2020
Patient Information leaflet Patient Information leaflet Slovak 07-12-2021
Public Assessment Report Public Assessment Report Slovak 26-06-2020
Patient Information leaflet Patient Information leaflet Slovenian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 07-12-2021
Public Assessment Report Public Assessment Report Slovenian 26-06-2020
Patient Information leaflet Patient Information leaflet Finnish 07-12-2021
Public Assessment Report Public Assessment Report Finnish 26-06-2020
Patient Information leaflet Patient Information leaflet Swedish 07-12-2021
Public Assessment Report Public Assessment Report Swedish 26-06-2020
Patient Information leaflet Patient Information leaflet Norwegian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 07-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 07-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 07-12-2021
Patient Information leaflet Patient Information leaflet Croatian 07-12-2021
Public Assessment Report Public Assessment Report Croatian 26-06-2020

Search alerts related to this product

View documents history